Inventory of Roche's key products listed in China

When it comes to Roche, the first thing we think about is Roche's blood glucose meter?! Yes, Roche from Basel, Switzerland is not only the world leader in pharmaceutical business, but also the world leader in diagnostic business Roche has a history of 120 years As one of the world's top 500 enterprises and the world's largest biotechnology company, Roche pharmaceutical has the world's leading drugs in the fields of anti-tumor, immunity, anti infection and ophthalmology In particular, Roche's three anti-tumor drugs, namely, rituximab, avidin and Herceptin, have been listed as the world's best-selling anti-tumor drugs for many years in a row, which makes them remain the dominant position in the field of anti-tumor It is reported that in 2016, Roche's pharmaceutical business generated revenue of US $39.252 billion, while the total global sales of rituximab, avidin and Herceptin reached US $21.1 billion According to Renault's analysis of Roche's top 10 best selling drugs in 2016, the total sales volume of Roche's top 10 best selling drugs in 2016 was US $30.721 billion Except that the global sales volume of kadcyla ® approved in February 2013 has not exceeded US $1 billion, the sales volume of the other nine drugs has exceeded US $1 billion Among the top 10 best-selling drugs, there are 6 anti-tumor drugs (among them, rituximab can also be used as an immune system drug), 2 immune system drugs, 1 cardiovascular drug and 1 ophthalmic drug (see Table 1 for details) Among them, the cardiovascular drug actidase ® is the only thrombolytic drug approved by FDA for ischemic stroke It is worth mentioning that among the top 10 best-selling drugs mentioned above, except that trocaine is a small molecule drug, the other 9 are all biological drugs It can be seen that Roche has great strength in biotechnology and anti-tumor field Table 1 notes of top ten best selling brand drugs of Roche in 2016: xolair was jointly developed by Roche and Novartis, with global sales of US $2.356 billion and Novartis sales of US $835 million in 2016; Lucentis was jointly developed by Roche and Novartis, with global sales of US $3.262 billion and Novartis sales of US $1.835 billion in 2016 In particular, among Roche's top 10 best selling drugs in 2016, except for perjeta ®, xolair ® and kadcyla ® which have not yet been imported into China, the other seven drugs have been imported into China Among them, the trade name of leizhumab in China is noside ®, the Chinese market is in the charge of Novartis, while the trade name of acticase ® in China is aitongli ®, and the Chinese market is in the charge of blinger Ingelheim In addition, Roche is currently conducting clinical trials of perjeta ® in China, and xolair, which is in charge of the Chinese market by Novartis, is also conducting clinical trials in China It is expected that the two drugs will enter the Chinese market in the near future According to Reynolds statistics, Roche's key varieties listed in China have 19 drugs, including 7 anti-tumor drugs, 4 anti infective drugs, 3 immune system drugs, 2 nervous system drugs, 1 digestive system, blood system and endocrine metabolism drugs (see Figure 1 for details) Figure 1 list of Roche's key varieties listed in China Among the 19 drugs listed in China, Roche has 6 biological drugs and 13 small molecule drugs The biological drugs are avidin, rituximab, yamelo, Herceptin, paroxetine and Rochman The small molecule drugs are zobov, Xeloda, troikae, borreli, Rocephin, Tamiflu, wansaiwei, semec, medoba, domegan, metoclopramide, Senecio, and rogaiquan (see Table 2 for details) It is worth mentioning that among the six biological drugs listed by Roche in China, except that the global sales of Pershing and Rockman in 2016 were less than US $1 billion, the other four drugs all exceeded US $1 billion Table 2 key recommended varieties of Roche's key drugs listed in China Next, Renault will make key recommendations for two types of Roche's drugs listed in China that have not yet been localized Trekkay lung cancer has become a common malignant tumor in the world, 80% of which are non-small cell lung cancer Trocaine is a small molecule tyrosine kinase inhibitor, which acts directly on the epidermal growth factor receptor (EGFR) It can inhibit the phosphorylation of tyrosine kinase in EGFR cut-off cells to achieve antitumor effect Clinical trials have confirmed that trocaine is effective in the treatment of advanced non-small cell lung cancer with few complications Trocaine was initially used in the second-line or third-line treatment of non-small cell lung cancer After further clinical trials, it was proved that trocaine can also benefit the survival of patients in the first-line and maintenance treatment In addition, trocaine can also be used to treat pancreatic cancer China's CFDA approved Roche's Troika to import into China in March 2007 So far, we have 10 years of clinical medication experience in China This product has not been localized at present, the main reason is limited by the original research patent However, the attention of domestic enterprises to this product is very high There are many star enterprises in China, including Jiangsu Haosen, Qilu, Zhengda Tianqing, Chongqing Huabang, Hangzhou Zhongmei Huadong, Fu'an pharmaceutical and Chongqing shenghuaxi, etc it is expected that domestic enterprises will continue to scramble for this product and the domestic market will be extremely fierce in the future Wansaiwei cytomegalovirus (CMV) retinitis is the most common ocular opportunistic infection in the late stage of AIDS, and it is the most serious complication of the eye With the increase of AIDS patients in China, people will no longer be unfamiliar with this disease In addition, the immune function of the transplant subjects is low due to a large number of immunosuppressants taken before and after the operation CMV specific cytotoxic T cells and auxiliary T cells have no immune response, they can not clear infection and produce immune protection, and they are prone to CMV active infection The active component of vancevir is valiganciclovir, which is the pre valine ester of ganciclovir Ganciclovir is a common anti CMV drug in clinic Intravenous administration can control CMV infection However, the oral bioavailability of genciclovine is poor, and it can only be injected in clinic The oral bioavailability of the modified valganciclovir was 10 times higher than that of ganciclovir After entering the human body, valganciclovir was rapidly hydrolyzed to ganciclovir to play the role of virus The main adverse reactions of wansaiwei were gastrointestinal and central nervous system symptoms, granulocytopenia and thrombocytopenia Wansaiwei was imported into China in August 2006 At present, it has 10 years of clinical medication experience in China This product has not been localized It is reported that at present, the enterprises that are developing this product include Hebei Renhe Yikang and Chongqing Shenghua Xi Although there are many approvals related to ganciclovir preparation in China, domestic enterprises pay very little attention to this product I wonder if this is related to Chinese drug habits? However, Renault believes that the domestic market prospect of this product should be very good.